Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often ...